Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771350 | 0.91 | HTT (0.55) | CYP1A2TDP1HTR1AHTTPOLB | |
| SCHEMBL1196794 | 0.85 | — | — | |
| SCHEMBL771501 | 0.78 | CYP1A2 (0.59) | CYP1A2TDP1EPHX2HPGD | |
| SCHEMBL5470776 | 0.77 | CYP1A2 (0.65) | CYP1A2TDP1HTR1APHGDHMGLL | |
| SCHEMBL4508546 | 0.74 | TDP1 (0.62) | CYP1A2TDP1HTR1APHGDHMGLL | |
| SCHEMBL13925516 | 0.74 | CYP1A2 (1.00) | CYP1A2TDP1HTR1APHGDHMGLL | |
| Hydrochloric Acid SCHEMBL15209250 | 0.74 | CYP1A2 (0.62) | CYP1A2TDP1HTR1APHGDHMGLL | |
| SCHEMBL15531 | 0.74 | TDP1 (0.62) | CYP1A2TDP1HTR1APHGDHMGLL | |
| SCHEMBL1965092 | 0.74 | CYP1A2 (0.62) | CYP1A2TDP1HTR1APHGDHMGLL | |
| SCHEMBL33260 | 0.74 | CYP1A2 (1.00) | CYP1A2TDP1HTR1APHGDHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397366-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | ARDELYX, INC. (US) | 2023-09-26 | — | — | US | claimed |
| US-20230273354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2023-08-31 | — | — | US | claimed |
| CN-116507628-A | Novel benzodiazepine compound, preparation method and application thereof | 中国药科大学 | 2023-07-28 | — | — | CN | claimed |
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-08-02 | — | — | US | claimed |
| CN-113966325-A | Fluorine-containing substituted imidazole salt compound, preparation method thereof, medicinal composition and application thereof | 厦门华绰生物医药科技有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-107660205-B | Heterocyclic compounds as LSD1 inhibitors | 因赛特公司 | 2021-08-27 | — | — | CN | claimed |
| US-20210163524-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2021-06-03 | — | — | US | claimed |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | claimed |
| CN-111909092-A | Fluorine-containing substituted imidazole salt compound, preparation method thereof, medicinal composition and application thereof | 厦门华绰生物医药科技有限公司 | 2020-11-10 | — | — | CN | claimed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1492536-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-05 | — | — | EP | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| WO-2004018451-A1 | PYRIDAZINONE-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | claimed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | claimed |
| US-6458779-B1 | TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-01 | — | — | US | claimed |
| US-6436919-B1 | LOCAL ANESTHETICS THAT HAVE LONGER DURATION OF ACTION WHILE REDUCING UNDESIRED SIDE EFFECTS | THERAVANCE INC. | 2002-08-20 | — | — | US | claimed |
| EP-1216243-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | Advanced Medicine, Inc. (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001025234-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | ADVANCED MEDICINE, INC. (US) | 2001-04-12 | — | — | WO | claimed |
| EP-0077720-B1 | BIPHENYL ALKYL CARBOXYLATED DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | PIERRE FABRE S.A. (FR) | 1984-07-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | CYP1A2 309/4885TDP1 874/4885HTR1A 1881/4885 |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | CYP1A2 309/4885TDP1 874/4885HTR1A 1881/4885 |
| US-20210163524-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | HSD11B2, HSD11B1, HSD3B2 | CYP1A2 84/4885TDP1 4153/4885HTR1A 3614/4885 |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | HSD11B2, HSD11B1, HSD3B2 | CYP1A2 84/4885TDP1 4153/4885HTR1A 3614/4885 |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | CYP1A2 381/4885TDP1 791/4885HTR1A 337/4885 |
| US-20230273354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | GRHPR, REN, GRK5 | CYP1A2 998/4885TDP1 4711/4885HTR1A 4191/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | CYP1A2 950/4885TDP1 2026/4885HTR1A 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.